All In Biotech

Drug Trial Radar · NCT03193398

BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy And Safety Study Of BTRX-246040 Administered Once Daily In Patients With Major Depressive Disorder With Or Without Anhedonia

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 104 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

104

Actual

Start

Jun 12, 2017

Primary completion

Nov 12, 2018

Study completion Dec 12, 2018

Sponsor

Lead sponsor
BlackThorn Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jun 20, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will determine the efficacy, safety, and tolerability of a once-daily (QD) dose of up to 80 mg of BTRX-246040 for 8 weeks in participants with MDD.

Conditions

  • Major Depressive Disorder

Interventions

  • BTRX-246040 oral capsule(s)Drug

    BTRX-246040 administered once daily to patients with MDD for 8 weeks

  • Placebo oral capsule(s)Drug

    administered once daily to patients with MDD for 8 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Investigator-administered MADRS Total Score From Baseline BTRX-246040 and PlaceboTime frame: Week 8

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • United States

    Cerritos, California

  • United States

    Garden Grove, California

  • United States, Florida

    Jacksonville, Florida

  • United States

    Lauderhill, Florida

  • United States, Florida

    Orlando, Florida

  • United States

    Libertyville, Illinois

  • United States

    Rochester, New York

  • United States

    Memphis, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.